AU2022271866A1 — Folate receptor-targeted conjugates with brush border membrane enzyme-cleavable linkers and methods of use in imaging and treating cancer
Assigned to Purdue Research Foundation · Expires 2023-12-07 · 2y expired
What this patent protects
A conjugate of formula (I) FRTL-BBMecL-AA or (II) FRTL-Alb-BBMecL-AA, wherein FRTL is a folate receptor-targeting ligand, BBMecL is a brush border membrane (BBM) enzyme-cleavable linker, Alb is an albumin-binder moiety, and AA is an active agent; composition comprising same; and …
USPTO Abstract
A conjugate of formula (I) FRTL-BBMecL-AA or (II) FRTL-Alb-BBMecL-AA, wherein FRTL is a folate receptor-targeting ligand, BBMecL is a brush border membrane (BBM) enzyme-cleavable linker, Alb is an albumin-binder moiety, and AA is an active agent; composition comprising same; and method of imaging and/or treating a tumor.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.